Current Report Filing (8-k)
August 09 2019 - 4:53PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
August 9, 2019 (August 9, 2019)
Date of Report (Date of earliest event reported)
ELITE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its
charter)
Nevada
|
|
001-15697
|
|
22-3542636
|
(State or other jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of incorporation)
|
|
File Number
|
|
Identification No.)
|
165 Ludlow Avenue, Northvale, New Jersey
07647
(Address of principal executive offices)
(201) 750-2646
(Registrant’s telephone number, including
area code)
|
(Former name or former address, if changed since last report.)
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule
14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule
13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant
to Section 12(b) of the Act:
Title
of each class
|
|
Trading
Symbol(s)
|
|
Name
of each exchange on which registered
|
|
|
|
|
|
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On August 9, 2019, Elite Pharmaceuticals, Inc.
("Elite" or the “Company") filed its quarterly report on Form 10-Q for the quarter ended June 30, 2019 and,
thereafter, issued a press release announcing its financial results for that quarter. A copy of the press release is furnished
as Exhibit 99.1 hereto and is incorporated herein by reference.
As noted in the press release, the Company
will host a conference call at 10:00 AM Eastern Daylight Time (EDT) on Monday, August 12, 2019, to provide a general business update.
Elite will respond to various stockholder questions submitted prior to the call.
Conference Call Information
Date:
|
Monday, August 12, 2019
|
Time:
|
10:00 AM EDT
|
Dial-in numbers:
|
1-800-346-7359 (domestic)
|
|
1-973-528-0008 (international)
|
Conference number:
|
98840
|
Questions:
|
dianne@elitepharma.com
by 12:00 PM EDT on Sunday, August 11, 2019
|
Audio Replay:
|
https://elite.irpass.com/events_presentations
|
Item 7.01 Regulation FD Disclosure.
The information disclosed in Item 2.02 above is incorporated into
this Item 7.01. The information included in this Current Report on Form 8-K (including the exhibit hereto) is being furnished
under Item 2.02, "Results of Operations and Financial Condition," Item 7.01, "Regulation FD Disclosure" and
Item 9.01 "Financial Statements and Exhibits" of Form 8-K. As such, the information (including the exhibit) herein shall
not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange
Act"), or otherwise subject to the liabilities of that Section, nor shall it be incorporated by reference into a filing under
the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing,
except as shall be expressly set forth by specific reference in such a filing. This Current Report (including the exhibit hereto)
will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements
of Regulation FD.
|
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits.
1
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
ELITE PHARMACEUTICALS, INC.
|
|
|
Dated: August 9, 2019
|
By:
|
/s/ Nasrat Hakim
|
|
|
Nasrat Hakim, President and CEO
|
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Elite Pharmaceuticals (QB) (USOTC:ELTP)
Historical Stock Chart
From Apr 2023 to Apr 2024